Long-term Results of Multimodal Therapy for Chronic Prostatitis/chronic Pelvic Pain Syndrome
2003; Lippincott Williams & Wilkins; Volume: 169; Issue: 4 Linguagem: Inglês
10.1097/01.ju.0000055549.95490.3c
ISSN1527-3792
AutoresDaniel A. Shoskes, Lukman Hakim, Gamal M. Ghoniem, Charles Lee Jackson,
Tópico(s)Hormonal and reproductive studies
ResumoNo AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Apr 2003Long-term Results of Multimodal Therapy for Chronic Prostatitis/chronic Pelvic Pain Syndrome DANIEL A. SHOSKES, LAWRENCE HAKIM, GAMAL GHONIEM, and CHARLES L. JACKSON DANIEL A. SHOSKESDANIEL A. SHOSKES , LAWRENCE HAKIMLAWRENCE HAKIM , GAMAL GHONIEMGAMAL GHONIEM , and CHARLES L. JACKSONCHARLES L. JACKSON View All Author Informationhttps://doi.org/10.1097/01.ju.0000055549.95490.3cAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Chronic prostatitis/chronic pelvic pain syndrome is a prevalent and multifactorial condition. Many patients have the condition for years despite conventional therapies. We assess the outcomes of multimodal therapy in patients with long-standing chronic prostatitis/chronic pelvic pain syndrome. Materials and Methods: A total of 53 patients with chronic prostatitis treated at our clinic with a minimum followup of 6 months were assessed by the National Institutes of Health-Chronic Prostatitis Symptom Index and by a global assessment score. Treatments included antibiotics, prostatic massage, anti-inflammatory phytotherapy, α-blockers and neuromuscular agents. Results: Mean age patient was 45 years and median symptom history was 3.5 years. Based on localizing cultures, and microscopy of urine and prostatic fluid 13% of the cases were category II, 41% were category IIIa and 46% were category IIIb. Mean followup from the last visit was 417 days (range 185 to 1,247). Mean changes ± SE from the initial to the final score on the National Institutes of Health-Chronic Prostatitis Symptom Index were 10.4 ± 3.3 to 5.9 ± 4.4 for pain, 4.2 ± 2.9 to 2.0 ± 2.7 for urinary, 8.2 ± 2.9 to 4.7 ± 3.4 for quality of life and 22.7 ± 6.6 to 13.2 ± 9.5 for total score (p <0.0001). Based on a global subjective assessment 43 of the patients (80%) were better, 8 were the same and 3 were worse. At final assessment 39% of the patients were on no therapy, 22% were on an α-blocker, 37% were on quercetin, 13% were on neuromuscular agents and 9% were on antibiotics. Conclusions: An approach using stepwise therapy with antibiotics, anti-inflammatories and neuromuscular agents can be successful in the majority of patients with long-standing chronic prostatitis. References 1 : Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med2001; 16: 656. Google Scholar 2 : Are there long term changes in symptoms over time in men with chronic prostatitis: An interim report from the Chronic Prostatitis Cohort (CPC) study. J Urol2001; 165: 24. abstract 100. Google Scholar 3 : The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol1999; 162: 369. Link, Google Scholar 4 : Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo-controlled, pilot study. Urology1999; 53: 502. Google Scholar 5 : Use of the bioflavonoid quercetin in patients with longstanding chronic prostatitis. J Am Neutraceut Ass1999; 2: 18. Google Scholar 6 : Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol1993; 71: 433. Google Scholar 7 : Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo-controlled study. Arch Ital Urol Androl1999; 71: 283. Google Scholar 8 : Use of antibiotics in chronic prostatitis syndromes. Can J Urol2001; 8: 24. Google Scholar 9 : Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol2001; 165: 1539. Link, Google Scholar 10 : Detection of bacterial signal by 16S rRNA polymerase chain reaction in expressed prostatic secretions predicts response to antibiotic therapy in men with chronic pelvic pain syndrome. Tech Urol2000; 6: 240. Google Scholar 11 : Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis. Crit Care Med1997; 25: 1392. Google Scholar 12 : Use of prostatic massage in combination with antibiotics in the treatment of chronic prostatitis. Prostate Cancer Prostate Dis1999; 2: 159. Google Scholar 13 : α-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol1998; 159: 883. Link, Google Scholar 14 : Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol1999; 162: 2014. Link, Google Scholar 15 : Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: correlation with gram positive bacterial growth and treatment response. J Androl2000; 21: 669. Google Scholar 16 : Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology1999; 54: 960. Google Scholar 17 : Correlation of β-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol2001; 166: 1738. Link, Google Scholar 18 : Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response. J Urol2002; 168: 331. Link, Google Scholar 19 : Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging2002; 19: 135. Google Scholar 20 : Management of chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am2002; 29: 235. Google Scholar From the Cleveland Clinic Florida, Weston and Nova Southeastern University, Ft. Lauderdale, Florida© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byPolackwich A, Li J and Shoskes D (2015) Patients with Pelvic Floor Muscle Spasm Have a Superior Response to Pelvic Floor Physical Therapy at Specialized CentersJournal of Urology, VOL. 194, NO. 4, (1002-1006), Online publication date: 1-Oct-2015.Mordasini L, Weisstanner C, Rummel C, Thalmann G, Verma R, Wiest R and Kessler T (2012) Chronic Pelvic Pain Syndrome in Men is Associated with Reduction of Relative Gray Matter Volume in the Anterior Cingulate Cortex Compared to Healthy ControlsJournal of Urology, VOL. 188, NO. 6, (2233-2237), Online publication date: 1-Dec-2012.ROWE E, SMITH C, LAVERICK L, ELKABIR J, WITHEROW R and PATEL A (2018) A PROSPECTIVE, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY OF PELVIC ELECTROMAGNETIC THERAPY FOR THE TREATMENT OF CHRONIC PELVIC PAIN SYNDROME WITH 1 YEAR OF FOLLOWUPJournal of Urology, VOL. 173, NO. 6, (2044-2047), Online publication date: 1-Jun-2005.SHOSKES D, THOMAS K and GOMEZ E (2018) ANTI-NANOBACTERIAL THERAPY FOR MEN WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME AND PROSTATIC STONES: PRELIMINARY EXPERIENCEJournal of Urology, VOL. 173, NO. 2, (474-477), Online publication date: 1-Feb-2005.SHOSKES D, LANDIS J, WANG Y, NICKEL J, ZEITLIN S and NADLER R (2018) IMPACT OF POST-EJACULATORY PAIN IN MEN WITH CATEGORY III CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROMEJournal of Urology, VOL. 172, NO. 2, (542-547), Online publication date: 1-Aug-2004.NICKEL J, DOWNEY J, ARDERN D, CLARK J and NICKEL K (2018) FAILURE OF A MONOTHERAPY STRATEGY FOR DIFFICULT CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROMEJournal of Urology, VOL. 172, NO. 2, (551-554), Online publication date: 1-Aug-2004. Volume 169Issue 4April 2003Page: 1406-1410 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsprostatepelvic painprostatitisantibioticscombined modality therapyMetricsAuthor Information DANIEL A. SHOSKES Financial interest and/or other relationship with Boehringer, Triurol and Roche. More articles by this author LAWRENCE HAKIM Financial interest and/or other relationship with Mentor Urology, Pfizer, Bayer, Lilly-Icos and American Medical Systems. More articles by this author GAMAL GHONIEM Financial interest and/or other relationship with Alza, Bioniche, Eli Lilly, Mentor, Pfizer, Pharmacia and Uroplasty. More articles by this author CHARLES L. JACKSON More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)